Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
146 hedge funds and large institutions have $515M invested in Eagle Pharmaceuticals, Inc. in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 55 increasing their positions, 53 reducing their positions, and 21 closing their positions.
4% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 53
1% more capital invested
Capital invested by funds: $508M → $515M (+$7.6M)
6% less funds holding
Funds holding: 155 → 146 (-9)
43% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$11.4M |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$9.38M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$5.86M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$4.97M |
| 5 |
BlackRock
New York
|
+$4.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$18.8M |
| 2 |
AC
Armistice Capital
New York
|
-$8.01M |
| 3 |
Two Sigma Investments
New York
|
-$5.31M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$3.55M |
| 5 |
Two Sigma Advisers
New York
|
-$3.49M |
EGRX Hedge Fund Activity: Q2 2021 in Review
146 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q2 2021, worth a combined $515M — up 1.5% from $508M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of EGRX and 12 opened new positions — a net loss of 9 holders — while 53 trimmed existing stakes and 55 added.
The largest buyer was JP Morgan Chase, adding an estimated $11.4M. The largest seller was Park West Asset Management, exiting entirely with an estimated $18.8M sold.
- 146 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q2 2021, down from 155 in Q1 2021.
- Funds reported $515M of Eagle Pharmaceuticals, Inc. stock for Q2 2021, up 1.5% quarter-over-quarter.
- 12 funds opened new Eagle Pharmaceuticals, Inc. positions in Q2 2021 and 21 closed out, a net change of -9 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q2 2021 was JP Morgan Chase, an estimated $11.4M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q2 2021 was Park West Asset Management, an estimated $18.8M sold.
Based on aggregated 13F filings for Q2 2021.